Cargando…

Usefulness of vonoprazan, a potassium ion-competitive acid blocker, for primary eradication of Helicobacter pylori

AIM: To investigate usefulness of triple therapy with vonoprazan, a potassium ion-competitive acid blocker and antibiotics, for Helicobacter pylori (H. pylori) eradication. METHODS: The H. pylori eradication rate was examined in 2507 patients (2055 undergoing primary eradication and 452 undergoing s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yamada, Shinya, Kawakami, Takumi, Nakatsugawa, Yoshikazu, Suzuki, Takahiro, Fujii, Hideki, Tomatsuri, Naoya, Nakamura, Hideki, Sato, Hideki, Okuyama, Yusuke, Kimura, Hiroyuki, Yoshida, Norimasa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2016
Materias:	Retrospective Cohort Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5095574/ https://www.ncbi.nlm.nih.gov/pubmed/27867688 http://dx.doi.org/10.4292/wjgpt.v7.i4.550

Ejemplares similares

Comparative study: Vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy
por: Sakurai, Kouichi, et al.
Publicado: (2017)

A Bile Duct Stone Formation around a Fish Bone as a Nidus after Pancreatoduodenectomy
por: Sakakida, Tomoki, et al.
Publicado: (2018)

Efficacy of Vonoprazan for Helicobacter pylori Eradication
por: Kiyotoki, Shu, et al.
Publicado: (2019)

Vonoprazan on the Eradication of Helicobacter pylori Infection
por: Huang, Jiaming, et al.
Publicado: (2023)

Comment On: Vonoprazan on the Eradication of Helicobacter pylori Infection
por: Düzenli, Tolga, et al.
Publicado: (2023)

Tailored eradication vs empirical bismuth-containing quadruple therapy for first-line Helicobacter pylori eradication: A comparative, open trial
por: Choi, Youn I, et al.
Publicado: (2019)

Late-onset severe biliary bleeding after endoscopic pigtail plastic stent insertion
por: Yasuda, Muneji, et al.
Publicado: (2017)

Role of Vonoprazan in Helicobacter pylori Eradication Therapy in Japan
por: Sugimoto, Mitsushige, et al.
Publicado: (2019)

RE: Comment On: Vonoprazan on the Eradication of Helicobacter pylori Infection
por: Huang, Jiaming, et al.
Publicado: (2023)

Effect of Age on Effectiveness of Vonoprazan in Triple Therapy for Helicobacter pylori Eradication
por: Kusunoki, Maho, et al.
Publicado: (2019)

Disease trends after Helicobacter pylori eradication based on Japanese nationwide claims and the health check-up database
por: Mizukami, Kazuhiro, et al.
Publicado: (2023)

Role of potassium-competitive acid blockers in eradication of Helicobacter pylori infection
por: Kim, Tae Ho
Publicado: (2023)

The efficacy and mechanism of vonoprazan-containing triple therapy in the eradication of Helicobacter pylori
por: Zhang, Zinan, et al.
Publicado: (2023)

Vonoprazan-Associated Gastric Mucosal Redness in Non-Helicobacter pylori-Infected and Helicobacter pylori-Eradicated Stomach
por: Kubo, Kimitoshi, et al.
Publicado: (2021)

Current status of Helicobacter pylori eradication and risk factors for eradication failure
por: Yan, Tian-Lian, et al.
Publicado: (2020)

Helicobacter pylori infection in subjects negative for high titer serum antibody
por: Toyoshima, Osamu, et al.
Publicado: (2018)

First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin
por: Sue, Soichiro, et al.
Publicado: (2017)

Expectations for the Dual Therapy with Vonoprazan and Amoxicillin for the Eradication of H. pylori
por: Furuta, Takahisa, et al.
Publicado: (2023)

Increased 5-hydroxymethylcytosine is a favorable prognostic factor of Helicobacter pylori-negative gastric cancer patients
por: Fu, Ying-Li, et al.
Publicado: (2022)

Comment on “First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin”
por: Kashani, Negin, et al.
Publicado: (2018)

A Vonoprazan, Clarithromycin, and Metronidazole Regimen as Helicobacter pylori Eradication Therapy for Patients with Penicillin Allergy in Light of Clarithromycin Resistance
por: Adachi, Kazunori, et al.
Publicado: (2023)

Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study
por: Murakami, Kazunari, et al.
Publicado: (2016)

Response to: Comment on “First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin”
por: Sue, Soichiro, et al.
Publicado: (2018)

Comment #2 on “First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin”
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2018)

Evaluation of safety and pharmacokinetics of bismuth‐containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication
por: Huh, Ki Young, et al.
Publicado: (2021)

A randomized clinical study on the efficacy of vonoprazan combined with amoxicillin duo regimen for the eradication of Helicobacter pylori
por: Yang, Faming, et al.
Publicado: (2023)

Real-world efficacy of daclatasvir and asunaprevir with respect to resistance-associated substitutions
por: Fujii, Hideki, et al.
Publicado: (2017)

The Effect of Food on the Pharmacokinetics of the Potassium‐Competitive Acid Blocker Vonoprazan
por: Mulford, Darcy J., et al.
Publicado: (2021)

The Potential Benefits of Vonoprazan as Helicobacter pylori Infection Therapy
por: Miftahussurur, Muhammad, et al.
Publicado: (2020)

Second-line bismuth-containing quadruple therapy for Helicobacter pylori eradication and impact of diabetes
por: Kim, Sung Eun, et al.
Publicado: (2017)

Is a Potassium-Competitive Acid Blocker Truly Superior to Proton Pump Inhibitors in Terms of Helicobacter pylori Eradication?
por: Sue, Soichiro, et al.
Publicado: (2021)

The efficacy of vonoprazan combined with different dose amoxicillin on eradication of Helicobacter pylori: an open, multicenter, randomized clinical study
por: Lin, Yimin, et al.
Publicado: (2022)

Efficacy and Safety of Vonoprazan and Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis
por: Zhang, Wen-Lin, et al.
Publicado: (2023)

The efficacy and safety of vonoprazan–amoxicillin dual therapy in eradicating Helicobacter pylori: a systematic review and meta-analysis
por: Feng, Jia-Hui, et al.
Publicado: (2023)

Hepatitis C eradication with sofosbuvir leads to significant metabolic changes
por: Morales, Amilcar L, et al.
Publicado: (2016)

Outcomes of furazolidone- and amoxicillin-based quadruple therapy for Helicobacter pylori infection and predictors of failed eradication
por: Zhang, Ya-Wen, et al.
Publicado: (2018)

Kyoto classification in patients who developed multiple gastric carcinomas after Helicobacter pylori eradication
por: Sakitani, Kosuke, et al.
Publicado: (2020)

Beta-blockers and physical frailty in patients with end-stage liver disease
por: Kuo, Selena Z, et al.
Publicado: (2018)

Two-day enema antibiotic therapy for parasite eradication and resolution of symptoms
por: Roshan, Niloufar, et al.
Publicado: (2020)

Importance of Metronidazole in Vonoprazan-based Helicobacter pylori Treatment in Japan
por: Suzuki, Sho, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_36unksp52vb92f72aqqrpirg9f